2026-01-07 - Analysis Report
Okay, here's a breakdown of the Teladoc Health Inc (TDOC) analysis, based on the data you provided.

**0) Report in English:**

**1) Return Rate Comparison:**

*   **TDOC Overview:** Teladoc Health Inc. is a telehealth company providing virtual healthcare services.
*   **TDOC Cumulative Return:** -64.46%
*   **VOO (S&P 500) Cumulative Return:** 91.00%
*   **Divergence:** -155.5 (Relative Divergence: 0.7)

**Analysis:** TDOC has significantly underperformed the S&P 500. The divergence between the two is substantial. The relative divergence of 0.7 suggests the current divergence is near the lower end of its historical range.

**Alpha, Beta Analysis:**

| Year       | CAGR      | MDD  | Alpha    | Beta | Cap(B) |
|------------|-----------|------|----------|------|--------|
| 2016-2018  | 74.0%     | 52.9% | 71.0%    | 1.7  | 10.0   |
| 2017-2019  | 119.0%    | 52.9% | 101.0%   | 1.8  | 16.9   |
| 2018-2020  | 87.0%     | 52.9% | 66.0%    | 0.7  | 40.3   |
| 2019-2021  | -84.0%    | 60.6% | -127.0%  | 0.5  | 18.5   |
| 2020-2022  | -246.0%   | 83.0% | -244.0%  | 0.8  | 4.8    |
| 2021-2023  | -302.0%   | 83.0% | -303.0%  | 1.9  | 4.3    |
| 2022-2024  | -87.0%    | 72.3% | -107.0%  | 1.9  | 1.8    |
| 2023-2025  | -34.0%    | 65.6% | -96.0%   | 1.7  | 1.4    |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):** Shows strong growth in earlier periods (2016-2020) but significant decline in recent years.
*   **MDD (Maximum Drawdown):** High MDD values indicate substantial risk and volatility.
*   **Alpha:** Consistently negative Alpha in recent years suggests underperformance relative to its benchmark.
*   **Beta:** Beta fluctuates, indicating varying sensitivity to market movements. The betas in the most recent periods (1.7, 1.9, 1.9, 1.7) indicate TDOC is more volatile than the market in these periods.
*   **Cap(B):**  Market Cap has significantly decreased over the years.

**2) Recent Stock Price Fluctuations:**

*   **Current Close:** 7.05
*    **Last-market** 8.0, 'previousClose': 7.28, 'change': 9.89
*   **5-day SMA:** 7.02
*   **20-day SMA:** 7.334
*   **60-day SMA:** 7.7648

**Analysis:** The stock price is currently below all three moving averages (5-day, 20-day, and 60-day), suggesting a potential downward trend. The most recent market data shows price increase, which can be interpreted as short term rebound.

**3) Indicators:**

*   **MRI (Market Risk Indicator):** 0.8 (Medium Investment)
*   **RSI (Relative Strength Index):** 27.56 (Oversold)
*   **PPO (Percentage Price Oscillator):** -0.3152
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (133 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent Relative Divergence Change (20 days):** 0.7 (+) - Short-term increase
*   **Expected Return (%):** -9726.1%

**Analysis:**

*   The Market Risk Indicator suggests a medium investment risk.
*   The RSI indicates the stock is currently in oversold territory, which *could* suggest a potential for a price rebound.
*   The PPO indicates a short-term trend.
*   The recent relative divergence change indicates short-term upside.
*   The extremely negative expected return is concerning.

**4) Recent News & Significant Events:**

*   **[2026-01-06] When (TDOC) Moves Investors should Listen:** (Potentially discussing significant price movements and their implications).
*   **[2026-01-06] Noteworthy Tuesday Option Activity:** (Indicates active trading and potential volatility).
*   **[2025-12-13] Forget Teladoc and Buy This Healthcare Stock Instead:** (Negative sentiment, suggesting alternatives).
*   **[2025-12-22] Why Teladoc (TDOC) Stock Is Up Today:** (Positive news, potentially short-lived).
*   **[2026-01-05] Teladoc’s Telehealth Comeback: Stock Tries To Reboot As Wall Street Stays Cautious:** (Suggests a potential turnaround effort but with limited confidence).
*   **[2025-12-17] Teladoc Health (TDOC): Reassessing Valuation After New $13.6 Million ESOP Shelf Registration Filing:** (Focus on valuation and potential dilution due to employee stock options).

**Analysis:** The news is mixed. Some articles suggest potential for a turnaround, while others are negative, recommending alternative investments or focusing on valuation concerns. The option activity suggests possible short-term volatility.

**4-2) Analyst Opinions:**

*   **Consensus:** Hold
*   **Mean Rating:** 2.67 (~Hold)
*   **Number of Opinions:** 22
*   **Target Price (avg/high/low):** 9.15 / 12.00 / 7.00

**Analysis:**  Analysts, on average, have a "Hold" rating. The average target price is above the current price, suggesting potential upside, but the low target price is near current value. The lack of recent rating changes suggests a stable, albeit cautious, outlook.

**5) Recent Earnings Analysis:**

| 날짜       | EPS   | 매출        |
|------------|-------|-------------|
| 2025-10-30 | -0.28 | 0.63 B$     |
| 2025-07-30 | -0.19 | 0.63 B$     |
| 2025-05-01 | -0.53 | 0.63 B$     |
| 2024-10-31 | -0.19 | 0.64 B$     |
| 2025-10-30 | -0.19 | 0.64 B$     |

**Analysis:** Teladoc has consistently reported negative EPS (Earnings Per Share). Revenue has been relatively stable. These indicate lack of profit.

**6) Financial Information:**

Revenue and Profitability:

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30 | $0.63B    | 70.12%        |
| 2025-06-30 | $0.63B    | 69.85%        |
| 2025-03-31 | $0.63B    | 68.73%        |
| 2024-12-31 | $0.64B    | 70.50%        |
| 2024-09-30 | $0.64B    | 71.94%        |

Capital and Profitability:

| Quarter      | Equity    | ROE       |
|--------------|-----------|-----------|
| 2025-09-30 | $1.39B    | -3.56%    |
| 2025-06-30 | $1.42B    | -2.30%    |
| 2025-03-31 | $1.43B    | -6.52%    |
| 2024-12-31 | $1.49B    | -3.25%    |
| 2024-09-30 | $1.51B    | -2.21%    |

**Analysis:**

*   **Revenue:** Relatively stable revenue.
*   **Profit Margin:** Very high Profit Margin
*   **Equity:** Declining equity over the period.
*   **ROE (Return on Equity):** Consistently negative ROE, which confirms Teladoc has been loss making.

**7) Comprehensive Analysis:**

Teladoc (TDOC) presents a mixed picture. While it operates in a growing telehealth market, its financial performance and stock performance have been poor.

*   **Negative Performance:** The stock has significantly underperformed the S&P 500, with a large negative cumulative return and consistently negative Alpha.
*   **Financial Weakness:**  The company shows declining equity, negative ROE, and consistent negative EPS.  While revenue is relatively stable, the lack of profitability is a major concern.
*   **Market Sentiment:** Analyst opinions are neutral ("Hold"), and news articles present a mixed outlook, indicating a lack of strong conviction in a turnaround.
*   **Technical Indicators:** The RSI suggests the stock may be oversold, *potentially* indicating a short-term buying opportunity. However, the negative PPO and the position of the stock below its moving averages suggest a potential downtrend.
*   **Risk:** The high MDD values highlight the stock's volatility and risk.
* **Profit Margin:** Very high Profit Margin may indicates that TDOC has enough room for profitability if they are efficient about cost reduction.

**Conclusion:**  Based on the data provided, investing in TDOC appears risky. While there might be short-term trading opportunities (potential oversold bounce), the fundamental financial weaknesses and underperformance relative to the market suggest caution. The extremely negative expected return should be taken very seriously.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.